[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"covid-19-acute-respiratory-distress-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:covid-19-acute-respiratory-distress-syndrome":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100448768","phase-2-phase-2a-multiple-ascending-dose-study-in-hospitalized-patients-with-pneumonia-100448768",false,"NCT05123755","Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.","A Randomized, Double-blind, Placebo-controlled, Phase 2a Multiple Ascending Dose Study to Examine the Safety, Tolerability and Efficacy of AV-001 Injection in Patients Hospitalized With Pneumonia Due To COVID-19 or Other Respiratory Infections.","Inclusion Criteria:\n\n* Able and willing to give signed informed consent\n* Patients hospitalized with a presumed diagnosis of pneumonia of \\\u003C 48 hours duration requiring supplemental oxygen therapy. Eligible patients include those hospitalized for a separate non-infectious reason who subsequently develop a presumed pneumonia;\n* Radiologic imaging (chest x-ray, CT scan, etc.) evidence of pulmonary involvement with new and persistent or progressive and persistent infiltrate, consolidation or cavitation.\n\nSigns and symptoms:\n\nAt least 1 of the following signs:\n\n* respiratory rate \\> 30 breaths\u002Fmin;\n* fever (\\> 38.0ºC or \\> 100.4o F);\n* leukopenia (≤ 4,000 WBC\u002Fmm3 or leukocytosis (≥ 12,000 WBC\u002Fmm3);\n* adults ≥ 70 years of age; altered mental status with no other recognized cause;\n\nAND at least 1 of the following symptoms:\n\n* New onset of purulent sputum or change in character of sputum or increased respiratory secretions;\n* New onset or worsening cough, or dyspnea, or tachypnea;\n* Rales or bronchial breath sounds;\n\n  * Female patients of reproductive potential must be on an effective contraceptive method\n\nExclusion Criteria:\n\n* Pregnant and\u002For lactating women\n* Patients included in any other interventional trial\n* Use of endotracheal intubation and mechanical ventilation or extracorporeal membrane oxygenation (ECMO) at screening\n* Any concurrent serious medical condition or concomitant medication that would preclude participation in the study including but not limited to:\n\n  * Septic shock as defined by systolic blood pressure (SBP) \\\u003C 90 mmHg or diastolic blood pressure (DBP) of \\\u003C 60 mmHg;\n  * Multiple organ failure;\n  * Are moribund irrespective of the provision of treatments;\n  * Any significant bleeding disorder or vasculitis;\n  * Any serious, nonhealing wound, peptic ulcer or bone fracture;\n  * Liver cirrhosis;\n  * History of a hypertensive crisis or hypertensive encephalopathy, or current, poorly controlled hypertension or hypotension;\n  * Severe renal insufficiency or end stage renal disease as determined by estimated glomerular filtration rate \\\u003C30mL\u002Fmin\u002F1.73m2;\n  * ARDS risk factors of aspiration pneumonia, non-cardiac shock, trauma, blood transfusion or drug overdose.\n* Any thromboembolic event within the past 3 months;\n* Symptomatic congestive heart failure or symptomatic or poorly controlled cardiac arrhythmia \\> class II as per New York Heart Association (NYHA) classification;\n* History of autonomic disorders or uncontrolled hypotension\n* Hypersensitivity to drug products containing polyethylene glycol (PEG)\n* Any other condition which the Principal Investigator feels may jeopardize the safety of the patient or the objectives of the study","ALL","18 Years",{"count":19,"type":20},120,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study in patients who are hospitalized with presumed pneumonia requiring supplemental oxygen therapy. The purpose of this study is to examine the safety, tolerability and efficacy of AV-001 Injection administration daily to the earlier of day 28 or EOT (day prior to hospital discharge). A total of 120 eligible patients (20 patients in each of cohort 1, 2 and 3 and 60 patients in cohort 4) will be recruited from up to 25 participating institutions\u002Fhospitals. Patients will be randomized in a 1:1 ratio to receive either AV-001 Injection or AV-001 placebo Injection, together with standard of care (SOC).",[26,27,28,29,30,31],"Acute Respiratory Distress Syndrome","Viral or Bacterial Infections","Pneumonia","Pneumonia, Viral","Respiratory Infection","COVID-19 Acute Respiratory Distress Syndrome","RECRUITING","2026-02-24",{"date":35,"type":36},"2026-02-27","ACTUAL",{"date":38,"type":36},"2021-12-20",{"date":40,"type":20},"2026-06",{"name":42,"class":43},"Vasomune Therapeutics, Inc.","INDUSTRY",5,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":64,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":5},"100451918","cardiac-magnetic-resonance-tissue-characterization-in-covid-19-survivors-100451918","NCT05164744","Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors","Cardiac Magnetic Resonance for Tissue Characterization-Based Risk Stratification of Cardiopulmonary Symptoms, Effort Tolerance, and Prognosis Among COVID-19 Survivors","Inclusion Criteria:\n\n* Emergency room presentation and\u002For hospitalization with COVID-19 infection defined in accordance with established criteria as follows: SAR-CoV2 RT-PCR+ (severe acute respiratory syndrome coronavirus 2 reverse transcription polymerase chain reaction) and at least one of the following symptoms: dyspnea, cough, dysphagia, rhinorrhea, diarrhea, nausea\u002Fvomiting, myalgias, fever, syncope\u002Fpresyncope.\n\nExclusion criteria:\n\n* Contraindication to CMR (i.e. non-compatible pacemaker\u002Fdefibrillator) or gadolinium (known hypersensitivity, eGFR (estimated globular filtration rate) \\\u003C30 ml\u002Fmin\u002F1.73m2).\n* Inability to provide informed consent (e.g. cognitive impairment).\n* Unrelated condition (e.g. neoplasm) with life expectancy \\\u003C12 months prohibiting follow-up.\n* Patients with contraindications to gadolinium (known or suspected hypersensitivity, glomerular filtration rate \\\u003C 30 ml\u002Fmin\u002F1.73m2) will undergo non-contrast MRI but will not be excluded from this study.\n* Patients with known or suspected pregnancy based on Weill Cornell Radiology intake surveys (reviewed by a clinical RN (registered nurse), as well as research personnel) will be excluded from the protocol.",true,{"count":54,"type":20},510,"OBSERVATIONAL","The purpose of this study is to test if visualizing the heart with cardiac MRI\u002Fecho will be important in the understanding cardiac function and prediction of cardiopulmonary symptoms, physical effort tolerance, and outcomes in COVID-19 survivors. If successful, the research will allow us to identify the causes of lasting cardiopulmonary symptoms and begin developing cardiac and lung directed therapies accordingly.",[58,59,60,31,61,62,63],"COVID-19 Pneumonia","COVID-19","COVID-19 Respiratory Infection","COVID-19 Lower Respiratory Infection","COVID-19 Acute Bronchitis","Coronavirus Disease 2019",[65],"coronavirus disease 2019,","2026-01-20",{"date":68,"type":36},"2026-01-22",{"date":70,"type":36},"2021-07-01",{"date":72,"type":20},"2026-07-30",{"name":74,"class":75},"Weill Medical College of Cornell University","OTHER",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":59,"eligibilityCriteria":82,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100547003","passive-detection--sars-cov-2-covid-19-am-breathalyzer-protect-kiosk-for-operational-medicine-100547003","NCT06402318","Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine","A Prospective, Non-interventional, Observational Clinical Validation Study to Analytically Validate the A&M Breathalyzer PROTECT Kiosk Breath Capture System.","Inclusion Criteria:\n\n* Asymptomatic and symptomatic individuals 18 years and older\n* Receiving standard COVID-19, Flu and\u002For RSV screening and testing at BAMC\n* Do not have to be diagnosed with SARS-CoV-19 (COVID-19) but only be screened\n* Ability to understand consent\n\nExclusion Criteria:\n\n* Any individual under age of 18\n* Anyone unable to comply (or be assisted) with study procedures\n* Anyone not able to provide temperature thermal scan, and\u002For perform exhaled breath for approximately 8 seconds","89 Years",{"count":85,"type":20},100,"The primary objective of this effort will be to optimize and operationalize innovative passive surveillance systems and in parallel, the effort will identify, evaluate, and transition groundbreaking new technologies in diagnostics for operationalization.\n\nTo meet the objective and execute the deliverables for this program of effort, the A\\&M Breathalyzer PROTECT Kiosk will be tested, modified and validated at Brooke Army Medical Center (BAMC). The collaborative efforts between the PI, Dr. Michael Morris at BAMC and Co-Investigator Dr. Tony Yuan at USU- Center for Biotechnology (4D Bio3) will assess the passive detection technology and provide a capability survey of use-case scenarios for different operational settings.\n\nGoals:\n\n1. Optimization and operationalize the A\\&M Breathalyzer PROTECT Kiosk, portable mass spectrometer (MS) Detector for Deployment in Military Operational Medicine Environments. The Breathalyzer will be deployed to BAMC to test its detection capabilities of COVID-19 among symptomatic and asymptomatic COVID-19 carrier vs. those not infected compared to gold standard RT-PCR.\n2. Evaluate the passive sensing, breath capture system, built within the A\\&M Breathalyzer PROTECT Kiosk. The conversion of the active breath capture system, currently requires a straw that the subject breaths into, where then a series of sensors built in the Breathalyzer would automatically sample the exhaled breath within proximity for recent COVID-19 exposure. This task would conclude with a set of sensors and sensor inputs that would be analyzed by the Atomic AI platform built in the device. Field testing at BAMC is planned to determine the level of detection and discrimination for sensor combinations to SARS-CoV2 components and biomarkers detected. This testing would update the Atomic AI algorithm, within the device, to understand the accuracy of positive detection and the resulting sensitivities.",[59,88,58,60,31],"SARS CoV 2 Virus",[90,91,92,93,94,95],"Breathalyzer","COVID-19 detection","Diagnostic Product","Pulmonary","PROTECT Kiosk","Passive Detection","2025-12-03",{"date":98,"type":36},"2025-12-10",{"date":100,"type":36},"2023-12-27",{"date":102,"type":20},"2026-03-30",{"name":104,"class":75},"The Geneva Foundation",1]